KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Non-Current Deffered Revenue (2016 - 2023)

Palvella Therapeutics has reported Non-Current Deffered Revenue over the past 7 years, most recently at $18.7 million for Q4 2022.

  • Quarterly Non-Current Deffered Revenue fell 51.22% to $18.7 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $18.7 million through Dec 2022, down 51.22% year-over-year, with the annual reading at $18.7 million for FY2022, 51.22% down from the prior year.
  • Non-Current Deffered Revenue was $18.7 million for Q4 2022 at Palvella Therapeutics, up from $18.5 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $67.7 million in Q1 2018 and troughed at $18.5 million in Q3 2022.
  • The 5-year median for Non-Current Deffered Revenue is $44.2 million (2019), against an average of $43.6 million.
  • Year-over-year, Non-Current Deffered Revenue skyrocketed 109.4% in 2018 and then crashed 59.98% in 2022.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $53.3 million in 2018, then fell by 11.34% to $47.3 million in 2019, then fell by 24.03% to $35.9 million in 2020, then rose by 6.97% to $38.4 million in 2021, then plummeted by 51.22% to $18.7 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Non-Current Deffered Revenue are $18.7 million (Q4 2022), $18.5 million (Q3 2022), and $30.8 million (Q1 2022).